Sanofi considers selling majority stake in Opella

Sanofi has announced that it is in discussions with CD&R for a potential sale of 50% of its stake in Opella. This decision is part of its strategy to refocus on innovative medicines and vaccines. The success of the negotiations will depend on consultation with employee representative bodies.

Opella, with 11,000 employees, operates in 100 countries and has 13 production sites. Its portfolio includes notable brands such as Allegra and Doliprane. It ranks third worldwide in consumer healthcare products. Opella grew by 6.3% in 2023.

This project underlines Opella's independence as an entity within Sanofi, with dedicated resources and a focus on brands and the consumer.